STOCKHOLM, Sweden & RADNOR, PA – Immedica Pharma AB has announced its plan to acquire Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) in a transaction valued at approximately $151 million. The deal, which is expected to close in the first quarter of 2025, signifies a major step in Immedica’s global growth, particularly its entry into the North American market.
Through this merger, Immedica will gain commercial rights to ZTALMY® (ganaxolone) oral suspension, an FDA-approved treatment for seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients aged two and older. ZTALMY is also approved in Europe, the UK, and China, with additional regulatory clearances anticipated worldwide.
“This acquisition represents a transformative step in Immedica’s growth as a leader in rare diseases,” said Anders Edvell, M.D., Ph.D., CEO of Immedica. “ZTALMY strengthens our portfolio and marks our entry into the U.S., furthering our mission to address unmet medical needs in rare disease communities.”
The addition of ZTALMY provides Immedica with an immediate revenue-generating product in the rare neurology sector, along with an experienced U.S. commercial team. The company plans to continue expanding the availability of ZTALMY globally while enhancing care for patients with challenging conditions like refractory seizures.
Marinus Pharmaceuticals’ CEO Scott Braunstein, M.D., commented, “This acquisition allows ZTALMY to reach even more patients in need while delivering value to Marinus’ stockholders. I’m incredibly proud of our team’s efforts in achieving this milestone.”
Immedica’s cash tender offer values Marinus shares at $0.55 per share, and the transaction aligns with its strategy to accelerate revenue growth and strengthen its capabilities in delivering innovative treatments for patients with rare diseases.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.